{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:00:17Z","timestamp":1790308817278,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["Vici 09150182010007"],"award-info":[{"award-number":["Vici 09150182010007"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118492","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:07:13Z","timestamp":1790035633000},"page":"118492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Combination pharmacotherapy for MASH: Potential synergistic approaches"],"prefix":"10.1016","volume":"254","author":[{"given":"Dana A.","family":"Meije","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan G.","family":"Holleboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan F.J.","family":"van de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2026.118492_b0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.bcp.2026.118492_b0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s42000-021-00339-6","article-title":"Nonalcoholic fatty liver disease: lifestyle and quality of life","volume":"21","author":"Vachliotis","year":"2022","journal-title":"Hormones (Athens)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118492_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12071166","article-title":"Combination Therapies for Nonalcoholic Fatty Liver Disease","volume":"12","author":"Makri","year":"2022","journal-title":"J Pers Med."},{"key":"10.1016\/j.bcp.2026.118492_b0020","article-title":"Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies","volume":"10","author":"Dong","year":"2023","journal-title":"Front Med (Lausanne)."},{"issue":"2","key":"10.1016\/j.bcp.2026.118492_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.bcp.2026.118492_b0030","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology."},{"issue":"9","key":"10.1016\/j.bcp.2026.118492_b0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S2468-1253(23)00187-5","article-title":"NAFLD and liver-related events: does type 2 diabetes have a key role?","volume":"8","author":"Vilar-Gomez","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118492_b0040","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bcp.2026.118492_b0045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118492_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.gastro.2020.05.046","article-title":"Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?","volume":"165","author":"Ratziu","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bcp.2026.118492_b0055","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: Insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"issue":"21","key":"10.1016\/j.bcp.2026.118492_b0060","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118492_b0065","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118492_b0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2026.118492_b0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.118492_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2026.03.011","article-title":"The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors","author":"Gonzalez-Rellan","year":"2026","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.bcp.2026.118492_b0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","journal-title":"Endocr. Connect."},{"issue":"3","key":"10.1016\/j.bcp.2026.118492_b0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.21037\/hbsn-21-569","article-title":"Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trial","volume":"11","author":"Gastaldelli","year":"2022","journal-title":"Hepatobiliary Surg Nutr."},{"key":"10.1016\/j.bcp.2026.118492_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"issue":"3","key":"10.1016\/j.bcp.2026.118492_b0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.118492_b0105","doi-asserted-by":"crossref","unstructured":"Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V, Abdelmalek MF, Rodriguez-Araujo G, Landgren H, et al. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. Clin Gastroenterol Hepatol. 2024;22(1):124\u201334.e1.","DOI":"10.1016\/j.cgh.2023.04.003"},{"issue":"9","key":"10.1016\/j.bcp.2026.118492_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/ph18091276","article-title":"Acetyl-CoA Carboxylase Inhibitors for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"18","author":"Hasanatuludhhiyah","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118492_b0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.118492_b0120","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/439587","article-title":"Oxidative Stress-Induced Diseases via the ASK1 Signaling Pathway","volume":"2012","author":"Soga","year":"2012","journal-title":"Int J Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118492_b0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118492_b0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLARtrials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118492_b0135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.118492_b0140","unstructured":"Study of Semaglutide, and Cilofexor\/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND) ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04971785."},{"key":"10.1016\/j.bcp.2026.118492_b0145","article-title":"Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials","volume":"5(2):35","author":"Berto-Junior","year":"2026","journal-title":"Drugs and Drug Candidates."},{"issue":"2","key":"10.1016\/j.bcp.2026.118492_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118492_b0155","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118492_b0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118492_b0165","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118492_b0170","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2468-1253(26)00123-8","article-title":"Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial","volume":"11","author":"Loomba","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10504","key":"10.1016\/j.bcp.2026.118492_b0175","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bcp.2026.118492_b0180","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118492_b0185","unstructured":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 (NATiV3) ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04849728."},{"key":"10.1016\/j.bcp.2026.118492_b0190","unstructured":"BioSpace. Inventiva (Euronext Paris and Nasdaq: IVA). Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH\/NASH and T2D. Daix (France), Long Island City (New York, United States), March 18, 2024."},{"issue":"4","key":"10.1016\/j.bcp.2026.118492_b0195","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium-glucose cotransporters: Functional properties and pharmaceutical potential","volume":"11","author":"Sano","year":"2020","journal-title":"J Diabetes Investig."},{"issue":"17","key":"10.1016\/j.bcp.2026.118492_b0200","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118492_b0205","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41591-025-03722-7","article-title":"TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial","volume":"31","author":"Noureddin","year":"2025","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118492_b0210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118492_b0215","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2026.118492_b0220","unstructured":"Noureddin M, Alkhouri N, Lawitz E, Kowdley K, Loomba R, Sanchez W, Gonzalez-Rojas Y, et al. Topline Results from a 12-Week Phase 2a Trial (DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR) \u03b2 Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH. Abstract #5000. The Liver Meeting; 10-14 November 2023; Boston, MA."},{"issue":"11\u201312","key":"10.1016\/j.bcp.2026.118492_b0225","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/apt.70382","article-title":"Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and\/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial","volume":"62","author":"Noureddin","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118492_b0230","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70206","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction-Associated Steatohepatitis","volume":"18","author":"Lin","year":"2026","journal-title":"J. Diabetes"},{"issue":"12","key":"10.1016\/j.bcp.2026.118492_b0235","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/apt.70196","article-title":"Review Article: GLP-1 Receptor Agonists and Glucagon\/GIP\/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD","volume":"61","author":"Zafer","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118492_b0240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118492_b0245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118492_b0250","unstructured":"LIVERAGE\u2122: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH\/MASH Who Have Moderate or Advanced Liver Fibrosis ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06632444."},{"issue":"7","key":"10.1016\/j.bcp.2026.118492_b0255","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:22:45Z","timestamp":1790306565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":51,"alternative-id":["S0006295226008348"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118492","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination pharmacotherapy for MASH: Potential synergistic approaches","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118492"}}